Radioimmunoguided surgery with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal cancer

Pierluigi Percivale, Sergio Bertoglio, Paolo Meszaros, Federico Schenone, Marco Gipponi, Luciano Moresco, Maurizio Cosso, Fausto Badellino

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Sixty-four patients with recurrent or metastatic colorectal cancer underwent radioimmunoguided surgery (RIGS). Thirty patients (Group A) were preoperatively injected with radiolabeled monoclonal antibody (MAb) B72.3, a whole IgG1 that reacts with tumor-associated glycoprotein (TAG-72) antigen. Thirty-four patients (Group B) were given monoclonal antibody F023C5, an F(ab')2 which reacts with the carcinoembryonic antigen (CEA). The use of F(ab')2 antibodies ensured a lower time interval from the preoperative injection of the radiolabeled MAb to surgery. This interval was 22.7 days for Group A patients and 10.9 days for Group B patients. The correct RIGS identification of tumor sites occurred in 80.4% of Group A patients and in 92.6% of Group B patients. Additional information capable of modifying surgical strategy was obtained in 23.3% of Group A patients and in 8.8% of Group B patients. This difference was due to the different patterns of biodistribution and pharmacokinetics of the two MAbs. Although FO23C5 yields an improved diagnostic resolution for macroscopic tumor sites, we believe that B72.3 or other whole IgG1 should be the first choice for RIGS in recurrent or metastatic colorectal cancer patients.

Original languageEnglish
Pages (from-to)231-234
Number of pages4
JournalSeminars in Surgical Oncology
Volume15
Issue number4
DOIs
Publication statusPublished - Dec 1 1998

Fingerprint

Iodine
Colorectal Neoplasms
Monoclonal Antibodies
Immunoglobulin G
Carcinoembryonic Antigen
Neoplasms
Pharmacokinetics
Antigens
Injections
Antibodies

Keywords

  • Adenocarcinoma
  • Biopsy
  • Carcinoembryonic antigen
  • Colorectal neoplasms
  • False positive reactions
  • Immunohistochemistry
  • Intraoperative period
  • Iodine radioisotopes
  • Monoclonal antibodies
  • Neoplasm metastasis
  • Preoperative care
  • Radioimmunodetection
  • Radioimmunotherapy
  • Staining

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Radioimmunoguided surgery with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal cancer. / Percivale, Pierluigi; Bertoglio, Sergio; Meszaros, Paolo; Schenone, Federico; Gipponi, Marco; Moresco, Luciano; Cosso, Maurizio; Badellino, Fausto.

In: Seminars in Surgical Oncology, Vol. 15, No. 4, 01.12.1998, p. 231-234.

Research output: Contribution to journalArticle

Percivale, Pierluigi ; Bertoglio, Sergio ; Meszaros, Paolo ; Schenone, Federico ; Gipponi, Marco ; Moresco, Luciano ; Cosso, Maurizio ; Badellino, Fausto. / Radioimmunoguided surgery with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal cancer. In: Seminars in Surgical Oncology. 1998 ; Vol. 15, No. 4. pp. 231-234.
@article{a003839d4b6b48b5b3e71354cc75a132,
title = "Radioimmunoguided surgery with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal cancer",
abstract = "Sixty-four patients with recurrent or metastatic colorectal cancer underwent radioimmunoguided surgery (RIGS). Thirty patients (Group A) were preoperatively injected with radiolabeled monoclonal antibody (MAb) B72.3, a whole IgG1 that reacts with tumor-associated glycoprotein (TAG-72) antigen. Thirty-four patients (Group B) were given monoclonal antibody F023C5, an F(ab')2 which reacts with the carcinoembryonic antigen (CEA). The use of F(ab')2 antibodies ensured a lower time interval from the preoperative injection of the radiolabeled MAb to surgery. This interval was 22.7 days for Group A patients and 10.9 days for Group B patients. The correct RIGS identification of tumor sites occurred in 80.4{\%} of Group A patients and in 92.6{\%} of Group B patients. Additional information capable of modifying surgical strategy was obtained in 23.3{\%} of Group A patients and in 8.8{\%} of Group B patients. This difference was due to the different patterns of biodistribution and pharmacokinetics of the two MAbs. Although FO23C5 yields an improved diagnostic resolution for macroscopic tumor sites, we believe that B72.3 or other whole IgG1 should be the first choice for RIGS in recurrent or metastatic colorectal cancer patients.",
keywords = "Adenocarcinoma, Biopsy, Carcinoembryonic antigen, Colorectal neoplasms, False positive reactions, Immunohistochemistry, Intraoperative period, Iodine radioisotopes, Monoclonal antibodies, Neoplasm metastasis, Preoperative care, Radioimmunodetection, Radioimmunotherapy, Staining",
author = "Pierluigi Percivale and Sergio Bertoglio and Paolo Meszaros and Federico Schenone and Marco Gipponi and Luciano Moresco and Maurizio Cosso and Fausto Badellino",
year = "1998",
month = "12",
day = "1",
doi = "10.1002/(SICI)1098-2388(199812)15:4<231::AID-SSU9>3.0.CO;2-G",
language = "English",
volume = "15",
pages = "231--234",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Radioimmunoguided surgery with different iodine-125 radiolabeled monoclonal antibodies in recurrent colorectal cancer

AU - Percivale, Pierluigi

AU - Bertoglio, Sergio

AU - Meszaros, Paolo

AU - Schenone, Federico

AU - Gipponi, Marco

AU - Moresco, Luciano

AU - Cosso, Maurizio

AU - Badellino, Fausto

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Sixty-four patients with recurrent or metastatic colorectal cancer underwent radioimmunoguided surgery (RIGS). Thirty patients (Group A) were preoperatively injected with radiolabeled monoclonal antibody (MAb) B72.3, a whole IgG1 that reacts with tumor-associated glycoprotein (TAG-72) antigen. Thirty-four patients (Group B) were given monoclonal antibody F023C5, an F(ab')2 which reacts with the carcinoembryonic antigen (CEA). The use of F(ab')2 antibodies ensured a lower time interval from the preoperative injection of the radiolabeled MAb to surgery. This interval was 22.7 days for Group A patients and 10.9 days for Group B patients. The correct RIGS identification of tumor sites occurred in 80.4% of Group A patients and in 92.6% of Group B patients. Additional information capable of modifying surgical strategy was obtained in 23.3% of Group A patients and in 8.8% of Group B patients. This difference was due to the different patterns of biodistribution and pharmacokinetics of the two MAbs. Although FO23C5 yields an improved diagnostic resolution for macroscopic tumor sites, we believe that B72.3 or other whole IgG1 should be the first choice for RIGS in recurrent or metastatic colorectal cancer patients.

AB - Sixty-four patients with recurrent or metastatic colorectal cancer underwent radioimmunoguided surgery (RIGS). Thirty patients (Group A) were preoperatively injected with radiolabeled monoclonal antibody (MAb) B72.3, a whole IgG1 that reacts with tumor-associated glycoprotein (TAG-72) antigen. Thirty-four patients (Group B) were given monoclonal antibody F023C5, an F(ab')2 which reacts with the carcinoembryonic antigen (CEA). The use of F(ab')2 antibodies ensured a lower time interval from the preoperative injection of the radiolabeled MAb to surgery. This interval was 22.7 days for Group A patients and 10.9 days for Group B patients. The correct RIGS identification of tumor sites occurred in 80.4% of Group A patients and in 92.6% of Group B patients. Additional information capable of modifying surgical strategy was obtained in 23.3% of Group A patients and in 8.8% of Group B patients. This difference was due to the different patterns of biodistribution and pharmacokinetics of the two MAbs. Although FO23C5 yields an improved diagnostic resolution for macroscopic tumor sites, we believe that B72.3 or other whole IgG1 should be the first choice for RIGS in recurrent or metastatic colorectal cancer patients.

KW - Adenocarcinoma

KW - Biopsy

KW - Carcinoembryonic antigen

KW - Colorectal neoplasms

KW - False positive reactions

KW - Immunohistochemistry

KW - Intraoperative period

KW - Iodine radioisotopes

KW - Monoclonal antibodies

KW - Neoplasm metastasis

KW - Preoperative care

KW - Radioimmunodetection

KW - Radioimmunotherapy

KW - Staining

UR - http://www.scopus.com/inward/record.url?scp=0031789107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031789107&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2388(199812)15:4<231::AID-SSU9>3.0.CO;2-G

DO - 10.1002/(SICI)1098-2388(199812)15:4<231::AID-SSU9>3.0.CO;2-G

M3 - Article

C2 - 9829378

AN - SCOPUS:0031789107

VL - 15

SP - 231

EP - 234

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -